Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in …
Biotechnology
US, San Carlos [HQ]
Ratios
6 Records · Starting from 2018Margins, Growth Rates In %
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | - - | - - | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | - - | - - | |
|
EPS Growth
|
- - | 5.22 | -57.80 | -12.21 | -91.19 | -12.20 | |
| EPS USD | -115.00 | -109.00 | -172.00 | -193.00 | -369.00 | -414.00 | |
| Return on Assets (ROA) | -41.64 | -81.43 | -22.36 | -30.86 | -23.82 | -28.57 | |
| Return on Equity (ROE) | 51.08 | 50.29 | -25.39 | -35.24 | -25.13 | -32.43 | |
| Return on Invested Capital (ROIC) | 74.93 | 54.26 | -25.50 | -34.47 | -25.63 | -30.96 | |
| Solvency | |||||||
| Equity Ratio | - - | -100 | - - | - - | - - | - - | |
| Debt/Assets | 0.65 | 0.25 | - - | 5.18 | 1.78 | 2.08 | |
| Debt/Equity | -0.79 | -0.15 | - - | 5.91 | 1.88 | 2.36 | |
| Debt/EBITDA | 230.98 | 120.36 | 444.63 | 53.11 | 430.35 | 96.18 | |
|
Debt/Capitalization
|
-0.80 | -0.15 | - - | 5.58 | 1.85 | 2.30 | |
| Long-Term Debt/Capitalization | -0.28 | - - | - - | 3.89 | 1.25 | 1.75 | |
| Interest Debt per Share USD | 0.02 | - - | - - | 0.32 | 0.28 | 0.30 | |
| Debt Growth | - - | -64.85 | -100.00 | - - | 6.90 | 62.89 | |
| Liquidity | |||||||
| Current Ratio | 993.12 | 558.48 | 830.12 | 892.70 | 2,325.86 | 754.07 | |
| Quick Ratio | 984.51 | 535.43 | 824.78 | 860.74 | 2,300.74 | 745.73 | |
| Cash Ratio | 984.51 | 533.62 | 824.14 | 240.23 | 2,059.61 | 273.47 | |
| Operating Cash Flow Ratio | -400 | -400 | - - | -400 | -400 | -200 | |
| Turnover | |||||||
| Inventory Turnover | - - | -616.00 | -468.33 | -150.00 | -919.60 | - - | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | |
| Payables Turnover | - - | 36.49 | 4.72 | 26.64 | 93.89 | 69.73 | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | - - | - - | |
| Coverage | |||||||
| Interest Coverage | -47,377.33 | -135,382.50 | -1,279,728.57 | -1,481,000.00 | -11,612,800.00 | - - | |
| Asset Coverage | 14,000 | 34,000 | - - | 1,700 | 5,400 | 4,300 | |
| Cash Flow Coverage (CFGR) | -6,651.97 | -29,282.61 | - - | -723.31 | -950.88 | -1,015.57 | |
| EBITDA Coverage | -37,800 | -122,100 | -1,240,800 | -1,404,000 | -9,488,900 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -4.41 | -4.19 | -6.47 | -8.10 | -7.70 | -6.59 | |
|
Price/Earnings (P/E)
|
-22.7032 | -23.8814 | -15.4519 | -12.3419 | -12.9816 | -15.1678 | |
| Price/Earnings Growth (PEG) | - - | 457.73 | -26.73 | -101.09 | -14.24 | -124.38 | |
|
Price/Book (P/B)
|
-1,159.58 | -1,201.09 | 392.37 | 434.91 | 326.22 | 491.87 | |
| Price/Tangible Book (P/TB) | -1,159.58 | -1,201.09 | 392.37 | 434.91 | 326.22 | 491.87 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-2,197.22 | -2,710.01 | -2,910.21 | -1,017.54 | -1,823.54 | -2,055.83 | |
| Price/Free CF (P/FCF) | -2,076.32 | -2,643.01 | -2,839.86 | -965.41 | -1,763.10 | -1,673.17 | |
| Price/Operating CF (P/OCF) | -2,197.22 | -2,710.01 | -2,910.21 | -1,017.54 | -1,823.54 | -2,055.83 |